Výsledky vyhledávání - "Danielle Marcotulli"

Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience

Autor: Xue Geng, Gee Youn Kim, James K. McCloskey, Tara McCabe, Ming Tan, Rebecca Testi, Danielle Marcotulli, Jamie Koprivnikar, Grace Perry, Elizabeth Jones

Publikováno v: Blood. 136:49-50

Background Patients with secondary acute myeloid leukemia (sAML) have poor outcomes compared to those with de novo AML. In 2017, liposomal daunorubicin and cytarabine (CPX-351) was FDA approved for the treatment of adults with newly diagnosed AML wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d8af120e8e143aa5c7ab68db69d6d195
https://doi.org/10.1182/blood-2020-142891

Zobrazit plný text záznamu

Blinatumumab Induces Responses in Extramedulary B-Cell Acute Lymphoid Leukemia (B-ALL) and Lymphoid Blast Crisis Chronic Myelogenous Leukemia (CML), and Rarely Results in CD19 Negative Relapse

Autor: Grace Perry, Genique Stanislaus, Joelle Gagnon, Yen-Hong Kuo, Danielle Marcotulli, Maritess Aviador, James K. McCloskey, Jamie Koprivnikar, Elizabeth Jones

Publikováno v: Blood. 132:2703-2703

Background: Blinatumumab (B), a bi-specific T-cell engaging CD3-CD19 antibody construct, has shown significant activity in patients (pts) with B-cell acute lymphoblastic leukemia (B-ALL). Despite this improvement, uncertainties remain regarding the o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a46f884a342b3fdeb28a76ad204d0a34
https://doi.org/10.1182/blood-2018-99-120172

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání